238 related articles for article (PubMed ID: 35241571)
1. Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage.
van den Bosch A; Fransen N; Mason M; Rozemuller AJ; Teunissen C; Smolders J; Huitinga I
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35241571
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
3. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.
Luchetti S; Fransen NL; van Eden CG; Ramaglia V; Mason M; Huitinga I
Acta Neuropathol; 2018 Apr; 135(4):511-528. PubMed ID: 29441412
[TBL] [Abstract][Full Text] [Related]
4. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
[TBL] [Abstract][Full Text] [Related]
8. Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study.
Rise HH; Brune S; Chien C; Berge T; Bos SD; Andorrà M; Valdeolivas IP; Beyer MK; Sowa P; Scheel M; Brandt AU; Asseyer S; Blennow K; Pedersen ML; Zetterberg H; de Schotten MT; Cellerino M; Uccelli A; Paul F; Villoslada P; Harbo HF; Westlye LT; Høgestøl EA
Neuroimage Clin; 2022; 35():103099. PubMed ID: 35772194
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis.
Blandford SN; Galloway DA; Williams JB; Arsenault S; Brown J; MacLean G; Moore GRW; Barron J; Ploughman M; Clift F; Stefanelli M; Moore CS
Mult Scler Relat Disord; 2021 Jul; 52():103006. PubMed ID: 34004435
[TBL] [Abstract][Full Text] [Related]
10. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
12. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
[TBL] [Abstract][Full Text] [Related]
14. An updated histological classification system for multiple sclerosis lesions.
Kuhlmann T; Ludwin S; Prat A; Antel J; Brück W; Lassmann H
Acta Neuropathol; 2017 Jan; 133(1):13-24. PubMed ID: 27988845
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
Martin SJ; McGlasson S; Hunt D; Overell J
J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
[TBL] [Abstract][Full Text] [Related]
17. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
[TBL] [Abstract][Full Text] [Related]
18. Extensive acute axonal damage in pediatric multiple sclerosis lesions.
Pfeifenbring S; Bunyan RF; Metz I; Röver C; Huppke P; Gärtner J; Lucchinetti CF; Brück W
Ann Neurol; 2015 Apr; 77(4):655-67. PubMed ID: 25612167
[TBL] [Abstract][Full Text] [Related]
19. Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.
de Boer A; van den Bosch AMR; Mekkes NJ; Fransen NL; Dagkesamanskaia E; Hoekstra E; Hamann J; Smolders J; Huitinga I; Holtman IR
Acta Neuropathol; 2024 May; 147(1):90. PubMed ID: 38771530
[TBL] [Abstract][Full Text] [Related]
20. "Ependymal-in" Gradient of Thalamic Damage in Progressive Multiple Sclerosis.
Magliozzi R; Fadda G; Brown RA; Bar-Or A; Howell OW; Hametner S; Marastoni D; Poli A; Nicholas R; Calabrese M; Monaco S; Reynolds R
Ann Neurol; 2022 Oct; 92(4):670-685. PubMed ID: 35748636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
